SGO 2023 Conference Coverage on VuMedi


 

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients With Recurrent Platinum Refractory/Resistant Ovarian Cancer

86 views
April 14, 2023
Comments 0
Login to view comments. Click here to Login